Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586389 · ClinicalTrials.gov registry record
Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
A clinical trial of Non-hematologic Cancer, sponsored by Sequenom.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT02586389 is a study of Non-hematologic Cancer that is actively recruiting participants, run by Sequenom. The registered enrollment target is 3,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02586389, a study of Non-hematologic Cancer, is actively recruiting participants, sponsored by Sequenom.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
Conditions Studied
Study Locations (1)
Idaho
- Idaho Urology - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2027-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02586389
The ClinicalTrials.gov registry entry for NCT02586389 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-hematologic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02586389 reports 1 study location spanning 1 distinct geographic area - top geographies include Idaho.
Frequently Asked Questions
What is clinical trial NCT02586389 about?
NCT02586389 is a clinical study titled "Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay". This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
What is the current status of trial NCT02586389?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2015-10-13. Estimated completion is 2027-10-31.
What conditions does trial NCT02586389 study?
This clinical trial studies the following conditions: Non-hematologic Cancer.
Who is sponsoring clinical trial NCT02586389?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02586389 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.